Aremo subcutaneous 15mg contains concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), used for prophylaxis of bleeding episodes in patients aged 12 years and older with hemophilia A or B. Manufactured by Novo Nordisk Pharma, this injectable (YJ code: 6343458G1020) is supplied as a 15mg 1.5mL kit.
Aremo subcutaneous 15mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →